Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report

The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that have not secured pricing deals with the White House, with the announcement expected as soon as Thursday. The tariffs are based on a Section 232 investigation under national security grounds, affecting companies without agreements or active negotiations, although exemptions may be possible. Major drugmakers like Pfizer, Eli Lilly, and Johnson & Johnson have already negotiated deals to avoid these tariffs, with J&J also committing to a $55 billion U.S. investment. This tariff initiative is part of a broader strategy to lower drug prices, including the launch of the TrumpRx platform for comparing discounted drug prices.